Biomedical subjects
Publications and source records attributed to Steven Gilberg.
Giant cell arteritis (GCA) presents clinically as an enlarged, tender, non-pulsatile temporal artery with associated headache and systemic symptoms. We present an unusual case of a patient with an enlarged temporal artery in the absence of other clinical findings. An atypical biopsy result provided the diagnosis and guided treatment.
BACKGROUND: Lacrimal gland lymphoproliferative disorders are usually classified as orbital adnexal tumours. Because the lacrimal gland is the only orbital structure with native lymphocytes, we examined cases with primary involvement of the gland. METHODS: The 14 cases were selected from a review of all cases in the surgical pathology files of the Ottawa Hospital between 1992 and 2003. The lesions were categorized according to the latest World Health Organization classification of tumours of lymphoid tissues. We conducted a clinical, histopathological, immunohistochemical, immunophenotypic and molecular genetic analysis of the cases. RESULTS: The 8 female and 6 male patients, aged 20 to 88 (mean 60) years, were followed for an average of 4 years (range 11 months to 13 years). All presented with supratemporal orbital swelling. The 5 primary lymphomas, of mucosa-associated lymphoid tissue (MALT), were confined to the lacrimal gland (stage IE); 1 tumour transformed to diffuse large B-cell lymphoma, necessitating chemotherapy, and the other 4 were treated with radiation. One of the 5 patients had previously had Sjögren's syndrome. The 6 secondary lymphomas (4 follicular) presented either concurrently with systemic lymphoma or up to 12 years afterwards and were treated in a variety of ways; all the patients had an orbital relapse. At the last follow-up assessment, 6 of the patients with lymphoma had no evidence of disease, 3 were alive with disease, 2 had died (1 of lymphoma, the other with no evidence of disease), and the status of 1 patient was not known. Of the 3 patients with reactive proliferations, 2 had reactive lymphoid hyperplasia (associated with Sjögren's syndrome in 1), and 1 had Rosai-Dorfman disease. All 9 lymphomas that underwent molecular genetic analysis were of B-cell lineage, and 8 had a monoclonal rearrangement in the immunoglobulin heavy-chain gene (IgH); the 9th lymphoma showed an oligoclonal rearrangement. One lymphoma showed the t(14;18) translocation, typical of follicular lymphoma; no lymphoma showed the t(11;18) translocation, commonly found in MALT lymphoma (but only 2 cases were studied). Molecular genetic analysis was performed in 2 of the cases of reactive lymphoid hyperplasia: monoclonal IgH rearrangement was detected in 1 case (the patient with Sjögren's syndrome), oligoclonal rearrangement in the other. INTERPRETATION: Lacrimal gland lymphomas are B-cell tumours that develop in older adults. Primary tumours, a hIgH proportion of which have MALT characteristics, have a favourable prognosis. Molecular genetic studies may be useful when morphologic and immunophenotypic studies give equivocal results.
Explore the source record for details and available documents.
A 46-year old woman developed simultaneous central retinal artery occlusions (CRAOs) in Wegener granulomatosis (WG). She had presented six years earlier with xerostomia, skin rash, and arthralgias and received a diagnosis of Sjogren syndrome. Anti-neutrophilic cytoplasmic antibody (ANCA) was negative. Months prior to the CRAOs, she had developed hearing loss, proptosis, and scleritis that were not responsive to prednisone 50 mg/d. The CRAOs occurred while she was being treated at this dose level. ANCA was now positive. This is the 12th case of CRAO in WG and the 6th case of bilateral CRAOs reported in the English literature. It emphasizes that serious irreversible visual complications may occur even when the patient is being treated with substantial corticosteroid doses.
PURPOSE: To determine and compare the amount of force required to disrupt the integrity of various orbital implants. METHODS: Compression tests were carried out by using a servo-electrical universal testing system on orbital implants including aluminum oxide (Bioceramic implant, FCI, Issy-Les-Moulineaux, France), coralline hydroxyapatite (HA) (Bio-Eye, Integrated Orbital Implants, Inc., San Diego, CA, U.S.A.), bovine HA (Molteno M-Sphere, IOP Inc., Costa Mesa, CA, U.S.A.), synthetic HA (FCI3, FCI, Issy-Les-Moulineaux, France), Chinese HA (H + Y Comprehensive technologies, Philadelphia, PA, U.S.A.), polylactic acid (Kinsey Nash Corporation, Duluth, MN, U.S.A.), porous polyethylene (Medpor, Porex Surgical Inc., College Park, GA, U.S.A.), and polymethylmethacrylate. RESULTS: Two basic groups of implants were identified: those that eventually reach a critical compression point and collapse (coralline HA, aluminum oxide, synthetic FCI3 HA, bovine HA, Chinese HA, and polymethylmethacrylate), and those that do not collapse but gradually compress with increasing load (porous polyethylene, polylactic acid). For similar-sized implants, the critical collapse point was earliest for the FCI3 HA implant, followed by the coralline HA, aluminum oxide, and polymethylmethacrylate implants. Smaller-sized collapsible implants showed earlier critical collapse points than larger-sized implants of similar material. CONCLUSIONS: A technique was established to assess the force required to disrupt the integrity of various orbital implants that is reliable, unbiased, and repeatable with any orbital implant. Orbital implants of different materials and sizes demonstrate different degrees of integrity. It is important to use similar-sized implants when comparing the integrity of different implant materials because size influences the force required to overcome the structural integrity of the implant.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
PURPOSE: To assess the problems seen in 158 patients with coralline hydroxyapatite (HA) orbital implants (Bio-Eye). METHODS: A consecutive case series of 170 patients receiving coralline HA implanted by two surgeons over a 5-year period were reviewed. The authors analyzed age, type of surgery, implant size, peg system, follow-up duration, time of pegging, problems encountered, and treatment. RESULTS: Twelve patients were lost to follow-up after 5 months, leaving 158 patients who were followed from 6 to 130 months (average, 39 months). Problems in unpegged implants occurred in 36 (22.8%) patients. Discharge occurred in 18 (11.4%) patients, implant exposure in 12 (7.6%), socket discomfort in 1 (0.6%), conjunctival thinning in 3 (1.9%), chronic conjunctival swelling in 2 (1.3%), and implant infection in 3 (1.9%). Problems after pegging occurred in 68 (50.7%) of 134 patients: discharge in 27 (20.1%), pyogenic granuloma in 24 (17.9%), conjunctiva overgrowing the peg in 4 (3.0%), implant exposure around the sleeve in 5 (3.7%), clicking in 6 (4.5%), peg on an angle in 2 (1.5%), loose sleeve in 1 (0.7%), peg falling out in 18 (13.4%), popping peg in 1 (0.7%), poor transfer of movement in 3 (2.2%), pain with movement in 1 (0.7%), and implant infection in 2 (1.5%). CONCLUSIONS: The Bio-Eye orbital implant represents a porous orbital implant that is biocompatible with orbital tissues and allows fibrovascular ingrowth and improved motility when coupled to the overlying artificial eye. It is more expensive than other commercially available porous orbital implants, such as synthetic FCI3 HA, porous polyethylene (Medpor), and aluminum oxide (Bioceramic) implant. Problems encountered with its use are similar to those problems seen in patients with the synthetic FCI3 hydroxyapatite and aluminum oxide orbital implants.
PURPOSE: To assess the problems associated with the Bioceramic (Aluminum oxide, Al(2)O(3)) orbital implant. METHODS: A consecutive case series of 107 patients receiving a Bioceramic orbital implant by two surgeons over a 3-year period were reviewed. The authors analyzed patient age, type of surgery, size of implant, peg system, follow-up duration, time of pegging, complications encountered, and treatment. RESULTS: Seven patients were lost to follow-up after 2 months, leaving 100 patients who were followed from 3 to 38 months (average, 13.4 months). Three patients died during the follow-up period (one with 2 months' follow-up, one with 7 months' follow-up, and the third with 9 months' follow-up). Implant-related problems occurred in 11 (11%) patients. Discharge occurred in 5 (5%) patients, implant exposure in 2 (2%), socket discomfort in 1 (1%), trochleitis in 1 (1%), and conjunctival thinning in 2 (2%). Peg problems occurred in 11 (34.3%) of 32 pegged patients: discharge in 4 (12.5%) and in 1 patient (3.1%) each, pyogenic granuloma, conjunctiva overgrowing the peg, implant exposure around the sleeve, clicking, accumulation of black material, and broken peg during insertion. Infection did not occur in any patient. CONCLUSIONS: The Bioceramic orbital implant represents an alternative porous orbital implant that is biocompatible with orbital tissues, easy to manufacture, structurally strong, and less expensive than other commercially available porous orbital implants (e.g., Bio-Eye hydroxyapatite implant). Problems encountered with its use are similar to those seen with the Bio-Eye orbital implants but appear to occur less often. The incidence of exposure associated with the Bioceramic implant is less than that reported for the Bio-Eye.
PURPOSE: To report 5 patients with a black material accumulating in the conjunctiva around the titanium peg and sleeve systems. METHODS: Retrospective small case series. The clinical features of 5 patients were reviewed. Histopathologic analysis was performed on specimens from 3 patients. Neutron activation analysis was performed on 1 sample. RESULTS: Five asymptomatic patients with black material accumulating in the conjunctiva at the conjunctival-titanium peg interface were evaluated. All patients had a hydroxyapatite-coated titanium sleeve with a titanium peg in position. Histopathologic analysis performed on specimens from 3 patients revealed a mixed inflammatory cell infiltrate with focal areas of a black, foreign-appearing material showing birefringence under polarized light that was predominantly intracytoplasmic. This black material did not respond to bleaching, and in 2 patients, it showed positive staining for iron (Perls method). The material from one patient was evaluated by neutron activation analysis and was found to contain titanium, aluminum, and vanadium. In 18 to 48 months of follow-up, the presence of the material did not appear to be associated with any problems. CONCLUSIONS: The presence of a black substance accumulating in the conjunctiva around some titanium coupling posts is uncommon and appears to be without any consequence in 18 to 48 months of follow-up. Our analysis revealed this substance to be consistent with titanium alloy (Ti-6Al-4V).